< Back to latest news & events

Event

Webinar: Patent eligibility of AI-related pharmaceutical inventions and practical tips for its patent obtainment in Japan

November 2021

Event date: 1st December 2021

Join our webinar on 1st December, where speakers from Shiga, one of the leading IP firms in Japan, will present on ‘Patent eligibility of AI-related pharmaceutical inventions and practical tips for its patent obtainment in Japan’.

About the webinar

Digital transformation has been reshaping the pharmaceutical industry. Today, AI has helped explore novel uses of existing drugs, develop new drugs, and accelerate R&D activity in the industry.

In Japan, patent eligibility of AI-related inventions is less strict than that in EP practice. When AI has been applied to pharmaceuticals, issues on inventive step, support requirements, and enable requirements often arise as points to be overcome.

Our speakers will explain patent eligibility on combinations of AI and pharmaceutical inventions, suggesting some practical points of the JPO Examination Guidelines. They will then give listeners insight into some case examples of AI-related pharmaceutical patents in Japan.

Watch the webinar: 

Speakers

Dr. Masato Iida, Shiga

Fumio Takahashi, Shiga

Latest updates

The Antibody Series #5 | Epitope-defined antibody claims: when “binds to this epitope” becomes a risk of insufficiency

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews decisions made at the EPO; here, they reviewed an appeal in opposition proceedings after the revocation …

Read article

The Deity Shoes case: a question of design activity and the constraints on a designer’s freedom

The footwear brand Deity Shoes sought to enforce their Community Design rights, both registered and unregistered, against Mundorama Confort and Stay Design. However, Mundorama Confort and Stay Design found fault …

Read article

The Antibody Series #4 | pH points in antibody claims: when “same pH ” becomes an addition of matter

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions; in this case, they reviewed a revocation in opposition of a patent relating to …

Read article

The Antibody Series #3 | Antibody code names in claims: why “ACZ885” is not sufficient to define the antibody

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions. In this case, they examined a claim that identified an antibody by an internal …

Read article
Event - 3rd February 2026

HGF Brand & Design Conference 2026

Join us on 3rd February 2026 for HGF’s Brand & Design Conference, the must attend event for in-house legal teams, brand leaders, creatives, and innovators shaping the future of IP. …

Event details

Office Closed Dates December 2025 / January 2026

HGF Office Closed Dates December 2025 / January 2026   UK Thursday 25 and Friday 26 December 2025 CLOSED Thursday 1 January 2026* CLOSED * Friday 2 January 2026 – …

Read article
Event - 14th January 2026

Seminar on The aftermath of G1/24 - has anything changed?

HGF is hosting a The aftermath of G1/24 – has anything changed? Which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 14th January …

Event details

Zombie Fashion Brands

Episode 4 Zombie Fashion Brands  

Read article